Esophageal squamous carcinoma cell line and related application thereof

Abstract

The invention discloses an esophageal squamous carcinoma cell line and related application thereof, and relates to the field of biological medicine. According to the invention, two stable esophageal squamous carcinoma cell lines with relatively high purity are successfully established, and the preservation numbers of the esophageal squamous carcinoma cell lines are CGMCC No: 46307 and CGMCC No: 46308. The establishment of the two new esophageal squamous carcinoma cell lines makes up for the deficiency of mouse cells with sex difference of the same model in the research process of an esophageal squamous carcinoma animal model, and valuable experimental materials and tools are provided for subsequent research of esophageal squamous carcinoma. By deeply researching the biological characteristics and genetic backgrounds of the two cell lines, the pathogenesis of the esophageal squamous cell carcinoma and the effect of sex difference in the esophageal squamous cell carcinoma can be more comprehensively known, so that a new thought and a new method are provided for clinical treatment and prevention of the esophageal squamous cell carcinoma.

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to an esophageal squamous cell carcinoma cell line and related applications thereof. Background Art

[0002] Esophageal cancer is pathologically divided into squamous cell carcinoma and adenocarcinoma. Esophageal squamous cell carcinoma (ESCC) usually originates from the squamous epithelium of the esophagus. ESCC is characterized by rapid clinical progression and poor prognosis, with a 5-year relative survival rate of less than 30%. Surgical resection, radiotherapy, and chemotherapy are conventional treatments for ESCC. In recent years, immunotherapy combined with chemotherapy, especially the use of immune checkpoint inhibitors, has become the mainstream treatment for ESCC, especially in the advanced stage. However, the clinical benefit of this approach is limited, and the proportion of patients with complete remission is less than 40%. As the most effective and promising treatment approach, further research on its mechanism and clinical efficacy is needed to improve its effectiveness.

[0003] Gender differences in cancer incidence and mortality are evident, with male patients generally being more adversely affected than female patients. Esophageal cancer is one of the four major cancers with significant gender differences, with an absolute survival gap of more than 10% between male and female patients. Unlike other solid tumors, studies on gender differences in esophageal cancer remain scarce, one of the reasons being the lack of gender-differentiated ESCC cells isolated in the same animal model.

[0004] Due to the genetic and pathological similarities between mice and humans, preclinical data obtained from mouse models are crucial for advancing the study of new drug targets. Commonly used mouse models for ESCC include 4-nitroquinoline-1-oxide (4-NQO)-induced ESCC primary mouse model and tumor xenograft mouse model. The 4-NQO-induced ESCC primary mouse model takes a long time, so mouse-derived cell lines are essential for establishing syngeneic mouse models and studying immunosuppressive tumor microenvironments. Currently, there are three commonly used mouse-derived ESCC cells, mEC25 (derived from female mice in the 4NQO-induced ESCC primary mouse model), HNM007 (derived from a transgenic mouse model of unclear sex), and AKR (derived from a transgenic mouse model of unclear sex). However, the genotypic similarity between these three mouse ESCC cell lines and human-derived ESCC cell lines is unclear, and there is a lack of clear male mouse-derived ESCC cells.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide an esophageal squamous cell carcinoma cell line and related applications thereof.

[0007] The present invention is achieved in that:

[0008] In the first aspect, an embodiment of the present invention provides a cell line, the cell line is named mEC525M, classified and named as male esophageal squamous cell carcinoma mouse cell line, and is deposited in the General Microbiology Center of China Microorganism Culture Collection Administration, with a deposit number of CGMCC No: 46307 and a deposit date of December 24, 2024.

[0009] In a second aspect, an embodiment of the present invention provides a cell line, the cell line is named mEC586F, classified as a female esophageal squamous cell carcinoma mouse cell line, and deposited in the General Microbiology Center of the China Microorganism Culture Collection Administration, with a deposit number of CGMCC No: 46308 and a deposit date of December 24, 2024.

[0010] In a third aspect, an embodiment of the present invention provides a progeny cell, wherein the progeny cell line is obtained by passage of the cell line described in the preceding embodiment.

[0011] In a fourth aspect, an embodiment of the present invention provides a kit, comprising: the cell line described in the preceding embodiment and / or the cell line described in the preceding embodiment and / or the progeny cell described in the preceding embodiment.

[0012] In a fifth aspect, embodiments of the present invention provide the use of the cell line described in the preceding embodiments and / or the cell line described in the preceding embodiments and / or the progeny cells described in the preceding embodiments in preparing an esophageal cancer cell model, an esophageal cancer animal model or an organoid model.

[0013] In a sixth aspect, embodiments of the present invention provide use of the cell lines described in the preceding embodiments and / or the cell lines described in the preceding embodiments and / or the progeny cells described in the preceding embodiments in screening drugs for treating and / or preventing esophageal cancer.

[0014] In a seventh aspect, embodiments of the present invention provide use of the cell lines described in the preceding embodiments and / or the cell lines described in the preceding embodiments and / or the progeny cells described in the preceding embodiments in screening targets for drugs for treating and / or preventing esophageal cancer.

[0015] In an eighth aspect, embodiments of the present invention provide use of the cell line described in the preceding embodiments and / or the cell line described in the preceding embodiments and / or the progeny cells described in the preceding embodiments in screening detection reagents for evaluating the efficacy of drugs for treating and / or preventing esophageal cancer.

[0016] In a ninth aspect, embodiments of the present invention provide use of the cell line described in the preceding embodiments and / or the cell line described in the preceding embodiments and / or the progeny cells described in the preceding embodiments in screening or developing preparations for reversing drug resistance in esophageal cancer.

[0017] The present invention has the following beneficial effects:

[0018] The present invention successfully established two stable and high-purity esophageal squamous cell carcinoma cell lines, named mEC525M (derived from male mice) and mEC586F (derived from female mice). The establishment of these two new esophageal squamous cell carcinoma cell lines makes up for the lack of mouse cells with gender differences in the same model during the research of esophageal squamous cell carcinoma animal models, and provides valuable experimental materials and tools for subsequent research on esophageal squamous cell carcinoma. By deeply studying the biological characteristics and genetic background of these two cell lines, we can more comprehensively understand the pathogenesis of esophageal squamous cell carcinoma and the role of gender differences in it, thereby providing new ideas and methods for the clinical treatment and prevention of esophageal squamous cell carcinoma. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0020] Figure 1 To establish two new esophageal cancer cell lines of different sexes from mice; (A) Schematic diagram of the study design (created by BioRender.com); (B) Representative images of longitudinally sectioned mouse esophagus in male (upper) and female (lower) mouse models induced by 4-NQO; (C) Morphology of the fifth generation mEC525M (upper) and mEC586F (lower) cell lines; (D) Cell morphology of the twentieth generation mEC525M (upper) and mEC586F (lower) cell lines; (E) 2×10 6 mEC525M (upper) and mEC586F (lower) cells were implanted into C57BL / 6 mice (n=3) to establish a subcutaneous ESCC tumor model; (F) Gross appearance and growth curves of syngeneic mEC525M (left) and mEC586F (right) tumors;

[0021] Figure 2Functional differences among five mouse-derived esophageal squamous cell carcinoma (ESCC) cell lines; (A) Histogram showing the cell doubling time of five mouse-derived ESCC cell lines measured using Livecyte (Phasefocus, UK), and the data were analyzed using an unpaired t-test; (B) Growth curves of five mouse-derived ESCC cells measured using Livecyte, and the data were analyzed using an unpaired t-test; (C) Histogram showing the dry weight doubling time of five mouse-derived ESCC cells measured using Livecyte, and the data were analyzed using an unpaired t-test; (D) Time-dependent cell dry weight distribution of five mouse-derived ESCC cells measured using Livecyte, and the data were analyzed using an unpaired t-test; (E-F) Random motion displacement (E) and trajectory velocity (F) of five mouse-derived ESCC cells measured using Livecyte, and the data were analyzed using an unpaired t-test;

[0022] Figure 3 Whole exome sequencing analysis revealed the molecular characteristics of five mouse-derived esophageal squamous cell carcinoma (ESCC) cell lines; (A-B) Venn diagrams showing the intersection of mutated genes between mEC525M (A) and mEC586F (B) cells and ESCC cells derived from three other mouse models; (C) Heat map of the top 30 genes based on mutation frequencies in our previous database; (D) Copy number variations (CNVs) of chromosomes 1-22 detected in the database; (E) Copy number variations of chromosomes 1-22 detected in five mouse-derived esophageal squamous cell carcinoma cell lines;

[0023] Figure 4 The differences in chemotherapy and radiotherapy sensitivity of five mouse-derived esophageal squamous cell carcinoma (ESCC) cell lines; (A) Inhibition curves of five mouse-derived ESCC cell lines after 24 hours of treatment with cisplatin or paclitaxel (measured by CCK8 method); (B) Growth curves of five mouse-derived ESCC cell lines after 72 hours of treatment with cisplatin or paclitaxel, measured by Incucyte live cell analysis technology; (C) Clone formation assay was used to detect and statistically analyze the proliferation of five mouse-derived ESCC cell lines after different doses of X-ray irradiation (0, 2 or 5Gy); data were analyzed using unpaired t-test;

[0024] Figure 5Figure 3 Differences in immune infiltration of five mouse-derived esophageal squamous cell carcinoma (ESCC) cells; (A) Scatter plots showing gating strategies for flow cytometry and cell sorting; (B) Representative flow cytometry (FACS) plots of T cell, B cell, and myeloid cell infiltration in syngeneic mEC525M and mEC586F tumors; (C) Percentages of T cell, B cell, and myeloid cell infiltration in syngeneic mEC525M and mEC586F tumors; Data are expressed as mean ± standard error (SEM) and analyzed using unpaired t-test;

[0025] Figure 6 Figure 3 Immune responses of mEC525M and mEC586F tumors to anti-PD-1 therapy; (A-B) Macroscopic appearance (A) and growth curves (B) of syngeneic mEC525M (left) and mEC586F (right) tumors treated with IgG (n=5) or anti-PD-1 (n=5); (C) Representative multiplex immunohistochemistry (mIHC) images and matching pseudo-hematoxylin and eosin images showing the expression of indicated marker genes in syngeneic mEC525M (left) and mEC586F (right) tumor tissues treated with IgG or anti-PD-1; (D) Box plots showing CD8 + T cells, CD4 + T cells and CD19 + The proportion of B cells. DETAILED DESCRIPTION

[0026] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0027] On the one hand, an embodiment of the present invention provides a cell line, the cell line is named mEC525M, classified and named as male esophageal squamous cell carcinoma mouse cell line, deposited in the General Microbiology Center of China Microorganism Culture Collection Committee, with a deposit number of CGMCC No: 46307, and a deposit address of No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, and a deposit date of December 24, 2024.

[0028] On the other hand, an embodiment of the present invention provides a cell line, the cell line is named mEC586F, classified and named as female esophageal squamous cell carcinoma mouse cell line, deposited in the General Microbiology Center of China Microorganism Culture Collection Administration, with a deposit number of CGMCC No: 46308, and a deposit address of the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and a deposit date of December 24, 2024.

[0029] mEC525M and mEC586F are ESCC cells with gender differences constructed based on the same mouse model. These two esophageal squamous cell carcinoma cell lines make up for the lack of mouse cells with gender differences in the same model during the research of esophageal squamous cell carcinoma animal models. They can be used to study the pathogenesis, drug resistance mechanism and gender differences of esophageal squamous cell carcinoma, providing a way for subsequent research and treatment of esophageal squamous cell carcinoma.

[0030] On the other hand, an embodiment of the present invention provides a progeny cell, wherein the progeny cell line is obtained by passage of the cell line described in any of the aforementioned embodiments.

[0031] On the other hand, an embodiment of the present invention provides a kit, comprising: the cell line mEC525M described in any of the foregoing embodiments and / or the cell line mEC586F described in any of the foregoing embodiments and / or the progeny cells described in any of the foregoing embodiments.

[0032] On the other hand, embodiments of the present invention provide use of the cell line mEC525M described in any of the preceding embodiments and / or the cell line mEC586F described in any of the preceding embodiments and / or the progeny cells described in any of the preceding embodiments in preparing an esophageal cancer cell model, an esophageal cancer animal model or an organoid model.

[0033] On the other hand, embodiments of the present invention provide use of the cell line mEC525M described in any of the preceding embodiments and / or the cell line mEC586F described in any of the preceding embodiments and / or the progeny cells described in any of the preceding embodiments in screening drugs for treating and / or preventing esophageal cancer.

[0034] On the other hand, embodiments of the present invention provide use of the cell line mEC525M described in any of the preceding embodiments and / or the cell line mEC586F described in any of the preceding embodiments and / or the progeny cells described in any of the preceding embodiments in screening drug targets for treating and / or preventing esophageal cancer.

[0035] On the other hand, embodiments of the present invention provide use of the cell line mEC525M described in any of the preceding embodiments and / or the cell line mEC586F described in any of the preceding embodiments and / or the progeny cells described in any of the preceding embodiments in screening detection reagents for evaluating the efficacy of drugs for treating and / or preventing esophageal cancer.

[0036] On the other hand, embodiments of the present invention provide use of the cell line mEC525M described in any of the foregoing embodiments and / or the cell line mEC586F described in any of the foregoing embodiments and / or the progeny cells described in any of the foregoing embodiments in screening or developing preparations for reversing drug resistance in esophageal cancer.

[0037] In some embodiments, the drug resistance comprises resistance to chemotherapy and / or radiotherapy.

[0038] In some embodiments, the esophageal cancer comprises esophageal squamous cell carcinoma.

[0039] As used herein, "treating" includes preventing or alleviating a condition, reducing the rate at which a condition develops or develops, reducing the risk of developing a condition, preventing or delaying the development of symptoms associated with a condition, reducing or stopping symptoms associated with a condition, producing complete or partial reversal of a condition, curing a condition, or a combination of the above.

[0040] For cancer, "treatment" can refer to inhibiting or slowing the growth, reproduction, or metastasis of tumors or malignant cells, or some combination of the above. For tumors, "treatment" includes eliminating all or part of the tumor, inhibiting or slowing tumor growth and metastasis, preventing or delaying the development of the tumor, or some combination of the above.

[0041] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0042] Example 1

[0043] Eight-week-old C57BL / 6J male and female mice were fed with 4-NQO solution at a concentration of 100 μg / mL for 16 weeks and then fed with normal water for 12 weeks. At the time of mouse euthanasia, multiple lesion areas present in the esophagus were picked, and tumor tissues were digested using a tumor dissociation kit (mouse, Miltenyi Biotec), resuspended in DMEM-F12 medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, and cultured in cell culture dishes ( Figure 1A in Figure 1). In order to limit the proliferation of fibroblasts and promote cancer cell growth, a two-step trypsin digestion method was used to separate tumor cells in the first five passages. In the next ten cell passages, ESCC cells were separated using a conventional one-step trypsin digestion method and cultured in complete DMEM medium. After 15 passages, the difference in attachment time between fibroblasts and ESCC cells was used to completely remove fibroblasts, and two stable mouse ESCC cell lines of different sexes were successfully established, named mEC525M (CGMCC No: 46307) and mEC586F (CGMCC No: 46308) ( Figure 1 Among them, mEC525M is derived from male mice, and mEC586F is derived from female mice.

[0044] To determine whether these two cell lines could be used to establish syngeneic mouse models of ESCC, their tumorigenicity was measured in C57BL / 6 mice. 6 mEC525M and mEC586F cells were injected subcutaneously into syngeneic C57BL / 6 mice. Seven days after injection, both cell types formed solid tumors in the mice, indicating that they are tumorigenic in vivo ( Figure 1 F), revealing that it can be used for in vivo study of esophageal squamous cell carcinoma.

[0045] Example 2

[0046] The cell doubling curves, dry matter doubling curves and movement trajectories of the two primary cell lines mEC525M and mEC586F were analyzed as follows, and HNM007, AKR and mEC25 cells were used as controls.

[0047] Reference Figure 2 In A to B, the cell doubling time of HNM007 and AKR cells is significantly shorter than that of the other three cell lines, indicating that HNM007 cells have the strongest proliferation ability, followed by AKR cells. The proliferation ability and cell doubling time of mEC525M cells and mEC586F cells are similar to those of mEC25 cells.

[0048] Dry matter is an important parameter that represents the total mass of all cellular components (including DNA, proteins, lipids and carbohydrates) excluding water. Figure 2 In Figures C and D, the dry weight doubling time of HNM007 and AKR cells was significantly shorter than that of the other three cell lines, and the dry weight growth ability of these two cells was also significantly stronger than that of the other three cell lines, which was consistent with the results of proliferation ability.

[0049] This example also uses ptychographic QPI (quantitative phase imaging) label-free imaging technology to obtain visualization results and measure cell movement. It was found that HNM007 and AKR cells had significantly stronger trajectory speed and movement ability than the other three cell types ( Figure 2 E and F in ).

[0050] These results indicate that mEC525M and mEC586F cells are highly similar to mEC25 cells in terms of proliferation, biomass synthesis, and motility, which may be because all three cell types were derived from the 4NQO-induced esophageal squamous cell carcinoma (ESCC) mouse model.

[0051] Example 3

[0052] Molecular characterization of five mouse-derived esophageal cancer cells.

[0053] In order to explore the molecular characteristics of mEC525M and mEC586F cells, whole exome sequencing (WES) was used to compare the differences in mutations and copy number variations (CNVs) between five mouse esophageal squamous cell carcinoma (ESCC) cell lines. Figure 3 As shown in A and B, mEC25 cells have the most mutated genes, while AKR cells have the least mutated genes. Among them, mEC525M and mEC586F cells show high similarity with mEC25 cells in terms of mutation.

[0054] To analyze the genotype similarity between mouse-derived and human esophageal squamous cell carcinoma cells, this example compares the WES dataset of mouse esophageal squamous cell carcinoma cells with the dataset collected from esophageal squamous cell carcinoma patients. When compared with the top 30 most mutated genes in esophageal squamous cell carcinoma patients based on mutation frequency, mEC586F and mEC25 cells had the largest number of mutated genes, and NOTCH1, KMT2D, FAT1, and FAT2 mutations were present in both cell types. However, no TP53 or CDKN2A mutations were detected in any of the five mouse esophageal squamous cell carcinoma cell lines ( Figure 3 C).

[0055] In terms of copy number variation, no known segmental amplification or deletion events, such as 11q13.3 amplification and 9p21.3 deletion, were detected in the five mouse esophageal squamous cell carcinoma cell lines. Figure 3In addition, AKR cells had the most abundant CNV changes, including amplification of chromosomes 6p, 7q, 10p, and 15p and loss of chromosomes 7p, 10p, 13p, and 15p, while HNM007 and mEC525M cells were relatively conservative. mEC586F cells showed high similarity with mEC25 cells in terms of copy number variation, which may be because they were both derived from 4NQO-induced female mouse models.

[0056] Example 4

[0057] Differences in chemotherapy and radiotherapy sensitivity among five mouse-derived esophageal cancer cells.

[0058] In recent years, chemotherapy regimens including cisplatin and paclitaxel have been widely used in patients with esophageal cancer, especially for patients in the middle and advanced stages who are not suitable for surgery. Therefore, this example compares the chemotherapy sensitivity of all five mouse esophageal squamous cell carcinoma cell lines. Figure 4 As shown in Figure A, HNM007 and AKR cells are more sensitive to cisplatin and paclitaxel than the other three cell lines. However, high doses of cisplatin and paclitaxel significantly inhibited the proliferation of these five cell lines ( Figure 4 B).

[0059] As a traditional treatment for esophageal cancer, radiotherapy is often used in combination with other treatments such as surgery, chemotherapy and immunotherapy, and is widely used in the treatment of patients with esophageal squamous cell carcinoma. This example further studied the differences in radiotherapy sensitivity of five types of mouse-derived esophageal cancer cells. Figure 4 As shown in (C), AKR and mEC25 cells were more sensitive to radiotherapy than the other three cell lines.

[0060] In summary, mEC525M and mEC586F cells are more suitable for studying the molecular mechanisms of chemotherapy and radiotherapy resistance.

[0061] Example 5

[0062] Differences in immune infiltration of five types of mouse-derived esophageal cancer cells.

[0063] The immunocompetent mouse tumor allograft model provides a convenient method for studying changes in the tumor microenvironment during antitumor immunity and developing new immunotherapy strategies. This example compares the differences in immune infiltration between five mouse-derived esophageal cancer cells ( Figure 5 A in Figure 5 As shown in Figures B and C, mEC525M tumors had the highest proportion of T cells, including CD4 + and CD8 +The proportion of these two T cells in mEC525M tumors was significantly higher than that in the other four tumor tissues. + The proportion of myeloid cells was significantly higher than that of the other four tumor tissues. As for B cells, CD19 + The proportion of B cells was significantly higher than that of the other four tumor tissues.

[0064] In summary, the percentages of immune cells in mEC25, mEC525M, and mEC586F tumors were higher than those in the other two tumors, and there were gender differences in the proportions of T cells, B cells, and myeloid cells.

[0065] Example 6

[0066] Immunotherapeutic efficacy testing of two primary cell lines.

[0067] To investigate the immune response of mEC525M and mEC586F tumors, C57BL / 6 mice were subcutaneously injected with mEC525M and mEC586F cells and treated with IgG or PD-1 antibody, respectively. Results from the syngeneic mouse model showed that anti-PD-1 treatment significantly reduced tumor volume and inhibited the growth of ESCC ( Figure 6 A and B in ).

[0068] To determine whether the enhanced antitumor effect of PD-1 blockade depends on T cell-mediated killing, multiplex immunohistochemistry (mIHC) analysis was performed on whole sections of tumor tissues from four different groups ( Figure 6 C). mIHC data showed that PD-1 treatment increased CD4 + and CD8 + In addition, in CD4 + In terms of T cells, the difference between the anti-PD-1 group and the IgG group was greater in mEC525M tumors than in mEC586F tumors; + In terms of T cells, the difference between the two groups was smaller in mEC525M tumors than in mEC586F tumors, suggesting that there are sex differences in the immune response mechanism. In addition, after anti-PD-1 treatment, CD20 + The proportion of B cells increased ( Figure 6 C and D in ).

[0069] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A cell line, characterized in that The cell line is named mEC525M, classified as male esophageal squamous cell carcinoma mouse cell line, and deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, with a deposit number of CGMCC No: 46307.

2. A cell line, characterized in that The cell line is named mEC586F, classified as female esophageal squamous cell carcinoma mouse cell line, and deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, with a deposit number of CGMCC No: 46308.

3. A progeny cell, characterized in that: The progeny cell line is obtained by subculturing the cell line according to claim 1 or 2.

4. A kit, characterized in that: It includes: The cell line of claim 1 and / or the cell line of claim 2 and / or the progeny cell of claim 3.

5. Use of the cell line according to claim 1 and / or the cell line according to claim 2 and / or the progeny cell according to claim 3 in preparing an esophageal cancer cell model, an esophageal cancer animal model or an organoid model.

6. Use of the cell line according to claim 1 and / or the cell line according to claim 2 and / or the progeny cell according to claim 3 in screening drugs for treating and / or preventing esophageal cancer.

7. Use of the cell line according to claim 1 and / or the cell line according to claim 2 and / or the progeny cell according to claim 3 in screening targets for drugs for treating and / or preventing esophageal cancer.

8. Use of the cell line according to claim 1 and / or the cell line according to claim 2 and / or the progeny cell according to claim 3 in screening a detection reagent for evaluating the efficacy of a drug for treating and / or preventing esophageal cancer.

9. Use of the cell line according to claim 1 and / or the cell line according to claim 2 and / or the progeny cell according to claim 3 in screening or developing a preparation for reversing drug resistance of esophageal cancer; Optionally, the drug resistance includes resistance to chemotherapy and / or radiotherapy.

10. The use according to any one of claims 5 to 9, characterized in that: The esophageal cancer includes esophageal squamous cell carcinoma.

Images